News Dyne Therapeutics, Inc.

Equities

DYN

US26818M1080

Real-time Estimate Cboe BZX Other stock markets 03:38:56 2024-05-10 pm EDT			5-day change	1st Jan Change
26.18 ^USD	+0.89%		-0.19%	+95.71%

May. 02	Dyne Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 30	Morgan Stanley Starts Dyne Therapeutics With Overweight Rating, $40 Price Target	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights	May. 02	GL
Dyne Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02	CI
Morgan Stanley Starts Dyne Therapeutics With Overweight Rating, $40 Price Target	Apr. 30	MT
Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer	Mar. 27	GL
Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium	Mar. 27	GL
Dyne Therapeutics President, CEO Joshua Brumm Resigns, John Cox Named Successor; Shares Drop 7% Pre-Bell	Mar. 25	MT
Dyne Therapeutics Announces CEO Transition	Mar. 25	GL
Dyne Therapeutics, Inc. Announces Management Changes	Mar. 25	CI
Dyne Therapeutics, Inc. Announces Chief Executive Officer Changes	Mar. 25	CI
Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days	Mar. 13	GL
Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days	Mar. 13	AQ
Chardan Raises Price Target on Dyne Therapeutics to $31 From $20 on Increased Confidence in Lead Assets for DM1, DMD, Keeps Buy Rating	Mar. 08	MT
Piper Sandler Adjusts Price Target on Dyne Therapeutics to $29 From $27, Maintains Overweight Rating	Mar. 06	MT
Stifel Adjusts Price Target on Dyne Therapeutics to $41 From $35, Maintains Buy Rating	Mar. 06	MT
Dyne Therapeutics Insider Sold Shares Worth $1,398,347, According to a Recent SEC Filing	Mar. 05	MT
Oppenheimer Adjusts Dyne Therapeutics Price Target to $47 From $44, Maintains Outperform Rating	Mar. 05	MT
Dyne Therapeutics's Q4 Net Loss Widens; Shares Down Pre-Bell	Mar. 05	MT
Dyne Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 05	CI
Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights	Mar. 05	GL
Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights	Mar. 05	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Dyne Therapeutics, Inc.

Equities

DYN

US26818M1080

Summary

Filters